

Press Release

Toa Eiyo Ltd.
Astellas Pharma Inc.

Launch of Biso[®] Tape in Japan, Transdermal Patch of β_1 Blocker, for The First Time in The World

Tokyo: September 9, 2013 - Toa Eiyo Ltd. (Tokyo; Unlisted; "Toa Eiyo") and Astellas Pharma Inc. (Tokyo: 4503; "Astellas") announced today that, on September 10, 2013, Toa Eiyo and Astellas will launch Biso[®] Tape 4 mg and Biso[®] Tape 8 mg (collectively, "Biso[®] Tape", nonproprietary name: bisoprolol), a transdermal patch of β_1 blocker for the first time in the world.

Biso[®] Tape, co-developed by Toa Eiyo and Nitto Denko Corporation, is a transdermal medication which contains 4 mg or 8 mg of bisoprolol, a β_1 selective blocking agent, and is the world's first transdermal patch of β_1 blocker and the first transdermal hypertension medication in Japan.

Biso[®] Tape has the following characteristics:

1. Hypertension* medicine in tape provides a new choice.

It is a transdermal patch of β_1 blocker for the first time in the world.

*The indication of Biso[®] Tape is essential hypertension (mild to moderate cases).

2. Antihypertensive effect for 24 hours.

Build up of blood concentration is gentle and provides antihypertensive effect for 24 hours through once-daily administration.

3. Dose-dependently controls blood pressure. Effective for 52 weeks.

Biso[®] Tape is available in 4 mg and 8 mg and the dose-dependent antihypertensive effect provides favorable blood pressure control for long periods.

4. Visible tape supports continuation of treatment.

The tape supports the continuation of treatment of patients with aspiration concerns and difficulties in maintaining medical compliance. It is also expected to improve medication adherence.

5. The main side-effects found in clinical trials in Japan were itchiness, dermatitis and erythema of applied region, and so on. Clinical trial abnormal value changes were blood triglyceride increase, ALT (GPT) increase, blood uric acid increase and eosinophil percentage increase, and so on.

Toa Eiyo is the marketing approval holder, Astellas will distribute and sell the product, and both companies will promote it.

Attachment: Product Outline

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201 http://www.astellas.com/en/

Product Outline

Bisono[®] Tape 4mg

Bisono[®] Tape 8mg

Product Name: Bisono[®] Tape 4mg and Bisono[®] Tape 8mg
 Nonproprietary Name: Bisoprolol
 Approval Date: June 28, 2013
 NHI Price Listing Date: August 27, 2013
 NHI Drug Price: Bisono[®] Tape 4mg: ¥ 89.3 (per 1 patch)
 Bisono[®] Tape 8mg: ¥ 123.0 (per 1 patch)
 Launch Date: September 10, 2013
 Composition:

Product Name	Bisono [®] Tape 4mg	Bisono [®] Tape 8mg
Content of Active Substance (per patch)	Bisoprolol 4 mg	Bisoprolol 8 mg
Inactive Substances	Polyisobutylene, isopropyl myristate, alicyclic saturated hydrocarbon	

Formulation: Transdermal patch
 Indication: Essential Hypertension (mild to moderate cases)
 Dosage Regimen: Under normal conditions, adult dosage of bisoprolol is 8 mg dose, once daily, applied to the chest, brachial or dorsal regions and changed every 24 hours. Depending on age and or symptoms, administration is to be commenced at 4 mg once daily, with a total dosage of no more than 8 mg per one day.
 Packaging: Bisono[®] Tape 4mg: 70 patches ((1 patch ×7) ×10)
 Bisono[®] Tape 8mg: 70 patches ((1 patch ×7) ×10)
 Marketing approval holder: Toa Eiyo Ltd.
 Distributor/Seller: Astellas Pharma Inc.

